Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Up 11.8% in November

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 239,900 shares, a growth of 11.8% from the October 31st total of 214,600 shares. Approximately 6.5% of the company's shares are sold short. Based on an average daily trading volume, of 75,900 shares, the short-interest ratio is presently 3.2 days.

Precision BioSciences Trading Down 5.8 %

Shares of DTIL stock traded down $0.42 during trading hours on Monday, reaching $6.87. The company's stock had a trading volume of 68,691 shares, compared to its average volume of 78,717. The stock has a market capitalization of $52.70 million, a P/E ratio of 114.50 and a beta of 1.71. Precision BioSciences has a one year low of $6.41 and a one year high of $19.43. The firm's fifty day simple moving average is $8.35 and its 200 day simple moving average is $9.64. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and issued a $60.00 price objective on shares of Precision BioSciences in a research report on Thursday, August 22nd.

Institutional Trading of Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC boosted its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) by 40.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,974 shares of the company's stock after acquiring an additional 19,088 shares during the period. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 37.99% of the company's stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.